
GIST
Latest News

Latest Videos

CME Content
More News

The combination of ziv-aflibercept and capecitabine demonstrated an acceptable safety profile and encouraging clinical efficacy for patients with metastatic colorectal cancer, according to findings from the ongoing phase II X-TRAP trial.

Tremelimumab as a monotherapy in both the second- and third-line treatment failed to boost overall survival (OS) compared with placebo for patients with unresectable malignant mesothelioma.

Everolimus (Afinitor) has received FDA approval for adult patients with progressive, well-differentiated non-functional, locally advanced or metastatic gastrointestinal (GI) or lung neuroendocrine tumors (NET), based on findings from the phase III RADIANT-4 trial.

Neoadjuvant therapy has become increasingly plausible for patients with advanced pancreatic cancer, as the quantity and quality of approved therapies continue to increase, according to Colin Weekes, MD, PhD.

A potential biomarker to guide the treatment of patients with metastatic colorectal cancer (mCRC) failed to stratify patients by progression-free survival (PFS) or responsiveness to bevacizumab, according to a randomized trial.

Complimenting best supporting care with panitumumab dropped the risk of death by 30% for patients with RAS wild-type chemorefractory metastatic colorectal cancer (mCRC).

Marginal improvements were seen in clinical outcomes for patients with metastatic colorectal cancer (CRC) treated with FOLFOXIRI plus bevacizumab compared with FOLFOX plus bevacizumab; however, these findings were inconsistent, according to results from the phase II STEAM trial.

Many patients with metastatic colorectal cancer (CRC) will ultimately progress on standard first- and second-line therapy while maintaining a good performance status, placing importance on the optimal use of third-line treatments.

Single-dose fosaprepitant dimeglumine (Emend for injection) in combination with antiemetic agents has been approved by the FDA for the preventing

Manish A. Shah, MD, a prominent researcher in the gastrointestinal cancer field who is helping to lead the BRIGHTER trial, discussed the ongoing research in an interview with Targeted Oncology.

Manish Shah, MD, Bartlett Family Associate Professor of Medicine, director, Gastrointestinal Oncology Program, Weill Cornell Medical College, discusses doing more than just surgery for patients with locally advanced stomach cancer.

<div style="color:#003668"><em>"When there is a mismatch between the human genetics and bacterial genetics, this may be one of the factors that leads to gastrointestinal cancer."<p align="right"><span style="color:#747474">- Keith Wilson, MD</span></em></div></p>

In patients with chemotherapy-refractory metastatic colorectal cancer (mCRC), ensituximab (NPC-1C), a chimeric immunoglobulin IgG1 monoclonal antibody, produced stable disease in almost half the patients in a phase II study, without contributing toxicity.

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, discusses the role genetic testing for colorectal cancer (CRC) plays in families.

Mismatch repair-deficient gastrointestinal (GI) tumors are highly responsive to checkpoint blockade with anti

The safety and efficacy profile of regorafenib in patients with previously treated colorectal cancer (CRC) is similar between US patients and the global study population enrolled in the phase IIIb CONSIGN study, according to Udit Verma, MD, at the 2016 Gastrointestinal Cancers Symposium.

Avelumab, an investigational anti-PD-L1 antibody, showed clinical activity as both a second-line and maintenance therapy in patients, with unresectable gastric or gastroesophageal junction (GEJ) cancer, according to data from a phase Ib presented at the 2016 Gastrointestinal Cancers Symposium.

Carboplatin/paclitaxel-based chemoradiotherapy (CarPacRT) has sufficient activity to progress into phase II clinical trials as neoadjuvant treatment for patients with resectable esophageal cancer.

































